Skip to main content

Table 2 Univariate and multivariate analysis of factors associated with time to recurrence and overall survival in two independent cohorts of human HCC

From: HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET

Cohort I (N = 260) Time To Recurrence Overall Survival
Clinical Variables HR(95%CI) P value HR(95%CI) P value
Univariate Analysis
 Age 0.982(0.969–0.995) 0.006 0.981(0.968–0.994) 0.005
 Sex (male versus female) 0.925(0.629–1.360) 0.692 0.873(0.593–1.286) 0.492
 Serum AFP (> 20 versus ≤ 20 ng/ml) 1.349(0.943–1.931) 0.102 1.405(0.970–2.036) 0.072
 HBV infection (yes versus no) 0.792(0.564–1.112) 0.178 0.767(0.543–1.081) 0.130
 Cirrhosis ( present versus absent) 0.903(0.647–1.259) 0.548 0.876(0.625–1.228) 0.442
 Child–pugh score (B versus A) 0.959(0.675–1.364) 0.818 0.948(0.661–1.358) 0.769
 Tumor number (multiple versus single) 1.961(1.447–2.656)  < 0.001 2.048(1.503–2.791)  < 0.001
 Maximal tumor size (> 5 versus ≤ 5 cm) 1.510(1.103–2.066) 0.010 1.573(1.139–2.173) 0.006
 Tumor encapsulation (absent versus present) 3.422(2.507–4.669)  < 0.001 3.584(2.607–4.927)  < 0.001
 Microvascular invasion (present versus absent) 3.111(2.280–4.245)  < 0.001 3.315(2.411–4.558)  < 0.001
 Tumor differentiation (III- IV versus I-II) 3.155(2.243–4.437)  < 0.001 3.363(2.385–4.743)  < 0.001
 TNM stage (III versus I-II) 6.680(4.741–9.414)  < 0.001 7.093(5.015–10.033)  < 0.001
 ETV1 (positive versus negative) 2.059(1.519–2.792)  < 0.001 2.143(1.571–2.922)  < 0.001
Multivariate analysis
 Tumor number (multiple versus single) 1.441(0.925–2.247) 0.106 1.530(0.973–2.406) 0.066
 Maximal tumor size (> 5 versus ≤ 5 cm) 1.417(0.966–2.078) 0.075 1.465(0.986–2.175) 0.059
 Tumor encapsulation (absent versus present) 1.335(0.840–2.121) 0.222 1.289(0.803–2.072) 0.293
 Microvascular invasion (present versus absent) 1.663(1.082–2.556) 0.020 1.808(1.168–2.800) 0.008
 Tumor differentiation (III- IV versus I-II) 1.569(1.075–2.288) 0.019 1.651(1.131–2.411) 0.009
 TNM stage (III versus I-II) 3.004(1.815–4.971)  < 0.001 3.004(1.796–5.026)  < 0.001
 ETV1 (positive versus negative) 1.651(1.201–2.269) 0.002 1.748(1.266–2.415) 0.001
Univariate Analysis
 Age 0.992(0.977–1.008) 0.327 0.988(0.972–1.003) 0.117
 Sex (male versus female) 1.080(0.695–1.678) 0.732 0.987(0.645–1.510) 0.952
 Serum AFP (> 20 versus ≤ 20 ng/ml) 0.951(0.657–1.377) 0.789 0.907(0.631–1.302) 0.595
 HBV infection (yes versus no) 2.203(1.380–3.519) 0.001 2.305(1.444–3.679)  < 0.001
 Cirrhosis ( present versus absent) 1.212(0.856–1.716) 0.278 1.242(0.878–1.756) 0.221
 Child–pugh score (B versus A) 1.359(0.924–1.999) 0.120 1.339(0.911–1.969) 0.137
 Tumor number (multiple versus single) 2.397(1.726–3.329)  < 0.001 2.391(1.724–3.316)  < 0.001
 Maximal tumor size (> 5 versus ≤ 5 cm) 2.511(1.839–3.429)  < 0.001 2.317(1.705–3.151)  < 0.001
 Tumor encapsulation (absent versus present) 3.058(2.239–4.177)  < 0.001 2.897(2.127–3.946)  < 0.001
 Microvascular invasion (present versus absent) 2.213(1.624–3.016)  < 0.001 2.268(1.668–3.083)  < 0.001
 Tumor differentiation (III- IV versus I-II) 3.539(2.561–4.890)  < 0.001 3.444(2.503–4.739)  < 0.001
 TNM stage (III versus I-II) 5.481(3.913–7.675)  < 0.001 5.875(4.196–8.225)  < 0.001
 ETV1 (positive versus negative) 2.218(1.629–3.020)  < 0.001 2.220(1.635–3.014)  < 0.001
Multivariate analysis
 Tumor number (multiple versus single) 1.272(0.852–1.898) 0.239 1.236(0.823–1.857) 0.307
 Maximal tumor size (> 5 versus ≤ 5 cm) 1.146(0.790–1.662) 0.473 1.013(0.704–1.456) 0.946
 Tumor encapsulation (absent versus present) 1.495(0.986–2.269) 0.059 1.394(0.923–2.105) 0.114
 Microvascular invasion (present versus absent) 1.475(0.995–2.188) 0.053 1.625(1.101–2.399) 0.015
 Tumor differentiation (III- IV versus I-II) 1.727(1.195–2.495) 0.004 1.696(1.180–2.437) 0.004
 TNM stage (III versus I-II) 2.968(1.885–4.672)  < 0.001 3.518(2.230–5.550)  < 0.001
 ETV1 (positive versus negative) 1.636(1.173–2.283) 0.004 1.638(1.180–2.274) 0.003